Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis

Rheumatology International

Volumn 31, Issue 2, 2011, Pages 243-245

  Takase, Kaoru ^a   Ohno, Shigeru ^a   Ideguchi, Haruko ^a   Uchio, Eiichi ^a   Takeno, Mitsuhiro ^b   Ishigatsubo, Yoshiaki ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Adalimumab; Beh et disease; Uveitis

Indexed keywords

ADALIMUMAB; CHLORPHENIRAMINE MALEATE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; METHYLPREDNISOLONE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAPHYLAXIS; ARTICLE; BEHCET DISEASE; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; UVEITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79954441287     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1178-y     Document Type: Article

References (14)

1. Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295-296 (Pubitemid 32738970)
2. Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 52:2478-2484 (Pubitemid 41117435)
3. Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368 (Pubitemid 38879203)
4. Sfikakis PP (2002) Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 (Suppl 2): ii51-ii53 (Pubitemid 35221714)
5. Sfikakis PP, Markomichelakis N, Alpsoy e et al (2007) Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 46:736-741 (Pubitemid 47061701)
6. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [comment]. Lancet 359:1541-1549 (Pubitemid 34621118)
7. Sands BE, Blank MA, Patel K et al (2004) Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2:912-920 (Pubitemid 39335798)
8. Papadakis KA, Shaye OA, Vasiliauskas EA et al (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100:75-79 (Pubitemid 41623272)
9. Oussalah A, Babouri A, Chevaux JB et al (2009) Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 29:416-423
10. Mushtaq B, Saeed T, Situnayake RD et al (2007) Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 21:824-825 (Pubitemid 46909189)
11. van Laar JA, Missotten T, van Daele PL et al (2007) Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 66:565-566 (Pubitemid 46580490)
12. Hale S, Lightman S (2006) Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33:231-237
13. Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18:481-486 (Pubitemid 351339402)
14. Theodossiadis PG, Markomichelakis NN, Sfikakis PP (2007) Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27:399-413 (Pubitemid 46624278)